Hepatitis C Drug Pipeline Discussed by PNS Pharma in Insightful Study Available at MarketPublishers.com
12 Nov 2013 • by Natalie Aster
LONDON – Over 350 thousand people worldwide die annually from diseases induced by the HCV (Hepatitis C virus). The disease affects nearly 3% of the global population, with an annual rate of infection standing at approximately 3-4 million. Low levels of awareness of Hepatitis C coupled with the insufficient knowledge of the disease are amid the main challenges to its prevention and control. The top market players are competing fiercely to take the lead in developing ground-breaking efficient therapies to fulfill unmet needs in the marketplace and eliminate key problems triggered by present-day treatments. Roche, Bristol-Myers Squibb, Merck, Vertex, GlaxoSmithKline, AbbVie, Idenix, Boehringer Ingelheim and Janssen are among the major companies involved in HCV drug development. A subsidiary of Roche, Anadys Pharmaceuticals, is currently developing ANA 773, which is designed for the treatment of chronic Hepatitis C infections.
The Hepatitis C market is anticipated to grow by nearly 230% through to 2022 to amount to USD 15.5 billion in 2022. The brisk growth in the sector is likely to be propelled by the rising prevalence of the disease and also by the surging demand for novel safer and more effective therapies.
Insightful research study “Hepatitis C Drug Pipeline Analysis” worked out by PNS Pharma provides a comprehensive overview of the drugs being developed for the treatment of Hepatitis C.
The report offers an extensive analysis of the Hepatitis C drug pipeline, covering all the ongoing drug development projects at various stages. Each drug profile discloses essential information, including the respective drug’s originator, owner, collaborator, technology provider, licensee, development phase, development indications, mechanism of action, chemical formula, country for clinical trial, pharmodynamics and pharmacokinetics, along with a detailed analysis on the development process. The research study assists in understanding the therapeutics associated with the Hepatitis C disease, identifying investment opportunities and also in keeping track of the current drug developments of the key competitors in the field.
Hepatitis C Drug Pipeline Analysis
Published: August, 2013
Price: US$ 1,800.00
Other Diseases Drug Pipeline Analyses by PNS Pharma Include:
- Pancreatic Cancer Drug Pipeline Analysis
- Ovarian Cancer Pipeline Analysis
- Malaria Disease Drug Pipeline Analysis
More in-demand market research reports by the publisher can be found at PNS Pharma page.